Kovac has been looking for a larger partner to help in the Cove in 19 vaccine race, and on Thursday it announced in Alliance with drugmaker buyer The to say the move will help cure VAX seek regulatory approval for its experimental inoculation on distribute doses.

Financial terms of the deal would not disclosed, but Cure back shares surged 14% following the news.

The firm last month started a late stage clinical trial of its covert 19 candidate, its banking on the same technology that has allowed rivals including Madonna, to progress with their vaccines.

The collaboration echoes a similar deal by German Peer By and Tech, also a research focused biotech firm.

It last year agreed to collaborate with global giant Pfizer on its vaccine, which is now being rolled out globally.

NASDAQ listed Kovac has said it aims to produce up to 300 million doses in 2021 up to 600 million in 2022.

Last year, it was at the center of a dispute over alleged attempts by Donald Trump to gain access to the vaccine, but the company denied having received any US offers for the company or its assets ahead of any regulatory approval.

The European Union has secured over 400 million doses of the cure back shot.